1. | Klug entscheiden – Eine Initiative der Deutschen Gesellschaft für Innere Medizin (DGIM). Deutsches Ärzteblatt 2021; 118: Sammelband April 2021. https://www.klug-entscheiden.com/fileadmin/user_upload/2021_Sammelband_Klug_entscheiden_Web_final.pdf (last accessed 13 April 2023). |
2. | https://dgim.de/veroeffentlichungen/klug-entscheiden/ (last accessed 13 April 2023). |
3. | Singh P, Arora A, Strand TA, et al.: Global Prevalence of Celiac Disease: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2018; 16: 823–36 CrossRef MEDLINE |
4. | Palmieri B, Vadala M, Laurino C: Gluten-free diet in non-celiac patients: beliefs, truths, advantages and disadvantages. Minerva Gastroenterol Dietol 2019; 65: 153–62. CrossRef MEDLINE |
5. | Melini V, Melini F: Gluten-Free Diet: Gaps and Needs for a Healthier Diet. Nutrients 2019; 11: 170. CrossRef MEDLINE PubMed Central |
6. | Leonard MM, Sapone A, Catassi C, et al.: Celiac Disease and Nonceliac Gluten Sensitivity: A Review. JAMA 2017; 318: 647–56. CrossRef MEDLINE |
7. | Welstead L: The Gluten-Free Diet in the 3rd Millennium: Rules, Risks and Opportunities. Diseases 2015; 3: 136–49. CrossRef MEDLINE PubMed Central |
8. | Felber J, Bläker H, Fischbach W, et al.: Aktualisierte S2k-Leitlinie Zöliakie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). Z Gastroenterol 2022; 60: 790–856. CrossRef MEDLINE |
9. | Castellsague J, Riera-Guardia N, Calingaert B, et al.: Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf 2012; 35: 1127–46. CrossRef MEDLINE PubMed Central |
10. | Yeomans ND, Lanas AI, Talley NJ, et al.: Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005; 22: 795–801. CrossRef MEDLINE |
11. | Gonzalez-Perez A, Saez ME, Johansson S, et al.: Risk factors associated with uncomplicated peptic ulcer and changes in medication use after diagnosis. PLoS One 2014; 9: e101768. CrossRef MEDLINE PubMed Central |
12. | Fischbach W, Bornschein J, Hoffmann JC, et al.: Aktualisierte S2k-Leitlinie Helicobacter pylori und gastroduodenale Ulkuskrankheit der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). Juli 2022 – AWMF-Registernummer: 021 – 001. https://register.awmf.org/assets/guidelines/021-001l_S2k_Helicobacter-pylori-gastroduodenale-Ulkuskrankheit_2022-07_1.pdf (last accessed 13 April 2023). |
13. | Kelly JP, Kaufman DW, Jurgelon JM, et al.: Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996; 348 (9039): 1413–16. CrossRef MEDLINE |
14. | Hernandez-Diaz S, Rodriguez LA: Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000; 160: 2093–99. CrossRef MEDLINE |
15. | Crooks CJ, West J, Card TR: Comorbidities affect risk of nonvariceal upper gastrointestinal bleeding. Gastroenterology 2013; 144: 1384–93. CrossRef MEDLINE PubMed Central |
16. | Weil J, Langman MJ, Wainwright P, et al.: Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut 2000; 46: 27–31. CrossRef MEDLINE PubMed Central |
17. | Gutthann SP, Garcia Rodriguez LA, Raiford DS: Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology 1997; 8: 18–24. CrossRef MEDLINE |
18. | Fischbach W: Medikamenteninduzierte gastrointestinale Blutung. Internist. 2019; 60: 597–607. CrossRef MEDLINE |
19. | Jarupongprapa S, Ussavasodhi P, Katchamart W: Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and non-selective, non-steroidal anti-inflammatory drugs plus proton pump inhibitors: a systematic review and meta-analysis. J Gastroenterol 2013; 48: 830–38. CrossRef MEDLINE |
20. | Rostom A, Muir K, Dube C, et al.: Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors. Drug Healthc Patient Saf 2009; 1: 47–71. CrossRef MEDLINE PubMed Central |
21. | Scally B, Emberson JR, Spata E, et al.: Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. Lancet Gastroenterol Hepatol 2018; 3: 231–41. CrossRef MEDLINE |
22. | Wang X, Tian HJ, Yang HK, et al.: Meta-analysis: Cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis. Eur J Gastroenterol Hepatol 2011; 23: 876–80. CrossRef MEDLINE |
23. | Rane PP, Guha S, Chatterjee S, et al.: Prevalence and predictors of non-evidence based proton pump inhibitor use among elderly nursing home residents in the US. Res Social Adm Pharm 2017; 13: 358–63. CrossRef MEDLINE |
24. | Hoffmann F, Glaeske G, Schmiemann G: Steigende Verordnungszahlen von Protonenpumpenhemmern im ambulant-ärztlichen Bereich über die Jahre 2005-2013. Z Gastroenterol 2015; 53: 95–100. CrossRef MEDLINE |
25. | Haastrup PF, Thompson W, Søndergaard J, et al.: Side Effects of Long-Term Proton Pump Inhibitor Use: A Review. Basic Clin Pharmacol Toxicol 2018; 123: 114–21. CrossRef MEDLINE |
26. | Targownik LE, Fisher DA, Saini SD. AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review. Gastroenterology 2022; 162: 1334–42. CrossRef MEDLINE |
27. | Beschluss der Bundesärztekammer über die Querschnitts-Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten, Gesamtnovelle 2020. Dtsch Arztebl 2020; 117 (40): A-1883/B-1603. VOLLTEXT |
28. | Carson JL, Sieber F, Cook DR, et al.: Liberal versus restrictive blood transfusion strategy: 3-year survival and cause of death results from the FOCUS randomised controlled trial. Lancet 2015; 385 (9974): 1183–89. CrossRef MEDLINE |
29. | Carson JL, Stanworth SJ, Denis JA, et al.: Transfusion thresholds for guiding red blood cell transfusion. Cochrane Database Syst Rev 2021; 12 (12): CD002042 CrossRef MEDLINE PubMed Central |
30. | Berger MD, Gerber B, Arn K, et al.: Significant reduction of red blood cell transfusion requirements by changing from a double-unit to a single-unit transfusion policy in patients receiving intensive chemotherapy or stem cell transplantation. Haematologica 2012; 97: 116–22. CrossRef MEDLINE PubMed Central |
31. | Leahy MF, Trentino KM, May C, et al.: Blood use in patients receiving intensive chemotherapy for acute leukemia or hematopoietic stem cell transplantation: the impact of a health system-wide patient blood management program. Transfusion 2017; 57: 2189–96. CrossRef MEDLINE |
32. | Amano K, Baracos VE, Hopkinson JB: Integration of palliative, supportive, and nutritional care to alleviate eating-related distress among advanced cancer patients with cachexia and their family members. Crit Rev in Oncol Hematol 2019; 143: 117–23. CrossRef MEDLINE |
33. | Tobberup R, Thoresen L, Falkmer UG, et al.: Effects of current parenteral nutrition treatment on health-related quality of life, physical function nutritional status, survival and adverse events exclusively in patients with advanced cancer: A systematic literature review. Crit Rev Oncol Hematol 2019; 139: 96–107. CrossRef MEDLINE |
34. | Arends J, Strasser F, Gonella S, et al.: Cancer cachexia in adult patients: ESMO Clinical Practice. ESMO Open 2021; 6 (3): 100092. CrossRef MEDLINE PubMed Central |
35. | Orrevall Y: Nutritional support at the end of life. Nutrition 2015; 31: 615–6. CrossRef MEDLINE |
36. | Arends J, Bachmann P, Bracos V, et al.: ESPEN guidelines on nutrition in cancer patients. Clin Nutr 2017; 36: 11–48 CrossRef MEDLINE |
37. | Arends J, Jordan K: Supplemental parenteral nutrition: decisions based on weak evidence. ESMO Open 2020; 5 (4): e000831. CrossRef MEDLINE PubMed Central |
38. | Raijmakers NJH, van Zuylen L, Costantini M, et al.: Artificial nutrition and hydration in the last week of life in cancer patients. A systematic literature review of practices and effects. Ann Oncol 2022; 22: 1478–86. CrossRef MEDLINE |
39. | Bouleuc C, Anota A, Cornet C, et al.: Impact on Health-related Quality of Life of Parenteral Nutrition for Patients with Advanced Cancer Cachexia: results from a Randomized Controlled Trial. Oncologist 2020; 25: e843–51. CrossRef MEDLINE PubMed Central |
40. | McCann RM, Hall WJ, Groth-Juncker A: Comfort care for terminally ill patients. The appropriate use of nutrition and hydration. JAMA 1994; 272: 1263–6. CrossRef MEDLINE |
41. | Chow R, Bruera E, Arends J, et al.: Enteral and parenteral nutrition in cancer patients a comparison of complication rates: an updated systematic review and (cumulative) meta-analysis. Support Care Cancer 2020; 28: 979–1010. CrossRef MEDLINE |
42. | Collet J-P, Thiele H, Barbato E, et al.: 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021; 42: 1289–367 CrossRef MEDLINE |
43. | Thiele H, Bauersachs J, Mehilli J, et al.: Kommentar zu den 2020er-Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) zum Management des akuten Koronarsyndroms bei Patienten ohne persistierende ST-Strecken-Hebung. Kardiologe 2021; 15: 19–31. CrossRef |
44. | Hindricks G, Potpara T, Dagres N, et al.: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC); Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42: 373–498 CrossRef MEDLINE |
45. | Rourke EJ: Ten Years of Choosing Wisely to Reduce Low-Value Care. New Engl J Med 2022; 386 (14): 1293–5. CrossRef MEDLINE |
Klug entscheiden in der Gastroenterologie

Literaturnachweise 2023
Literaturnachweise
-
1. Klug entscheiden – Eine Initiative der Deutschen Gesellschaft für Innere Medizin (DGIM). Deutsches Ärzteblatt 2021; 118: Sammelband April 2021. https://www.klug-entscheiden.com/fileadmin/user_upload/2021_Sammelband_Klug_entscheiden_Web_final.pdf (last accessed 13 April 2023). 2. https://dgim.de/veroeffentlichungen/klug-entscheiden/ (last accessed 13 April 2023). 3. Singh P, Arora A, Strand TA, et al.: Global Prevalence of Celiac Disease: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2018; 16: 823–36 CrossRef MEDLINE 4. Palmieri B, Vadala M, Laurino C: Gluten-free diet in non-celiac patients: beliefs, truths, advantages and disadvantages. Minerva Gastroenterol Dietol 2019; 65: 153–62. CrossRef MEDLINE 5. Melini V, Melini F: Gluten-Free Diet: Gaps and Needs for a Healthier Diet. Nutrients 2019; 11: 170. CrossRef MEDLINE PubMed Central 6. Leonard MM, Sapone A, Catassi C, et al.: Celiac Disease and Nonceliac Gluten Sensitivity: A Review. JAMA 2017; 318: 647–56. CrossRef MEDLINE 7. Welstead L: The Gluten-Free Diet in the 3rd Millennium: Rules, Risks and Opportunities. Diseases 2015; 3: 136–49. CrossRef MEDLINE PubMed Central 8. Felber J, Bläker H, Fischbach W, et al.: Aktualisierte S2k-Leitlinie Zöliakie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). Z Gastroenterol 2022; 60: 790–856. CrossRef MEDLINE 9. Castellsague J, Riera-Guardia N, Calingaert B, et al.: Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf 2012; 35: 1127–46. CrossRef MEDLINE PubMed Central 10. Yeomans ND, Lanas AI, Talley NJ, et al.: Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005; 22: 795–801. CrossRef MEDLINE 11. Gonzalez-Perez A, Saez ME, Johansson S, et al.: Risk factors associated with uncomplicated peptic ulcer and changes in medication use after diagnosis. PLoS One 2014; 9: e101768. CrossRef MEDLINE PubMed Central 12. Fischbach W, Bornschein J, Hoffmann JC, et al.: Aktualisierte S2k-Leitlinie Helicobacter pylori und gastroduodenale Ulkuskrankheit der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). Juli 2022 – AWMF-Registernummer: 021 – 001. https://register.awmf.org/assets/guidelines/021-001l_S2k_Helicobacter-pylori-gastroduodenale-Ulkuskrankheit_2022-07_1.pdf (last accessed 13 April 2023). 13. Kelly JP, Kaufman DW, Jurgelon JM, et al.: Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996; 348 (9039): 1413–16. CrossRef MEDLINE 14. Hernandez-Diaz S, Rodriguez LA: Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000; 160: 2093–99. CrossRef MEDLINE 15. Crooks CJ, West J, Card TR: Comorbidities affect risk of nonvariceal upper gastrointestinal bleeding. Gastroenterology 2013; 144: 1384–93. CrossRef MEDLINE PubMed Central 16. Weil J, Langman MJ, Wainwright P, et al.: Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut 2000; 46: 27–31. CrossRef MEDLINE PubMed Central 17. Gutthann SP, Garcia Rodriguez LA, Raiford DS: Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology 1997; 8: 18–24. CrossRef MEDLINE 18. Fischbach W: Medikamenteninduzierte gastrointestinale Blutung. Internist. 2019; 60: 597–607. CrossRef MEDLINE 19. Jarupongprapa S, Ussavasodhi P, Katchamart W: Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and non-selective, non-steroidal anti-inflammatory drugs plus proton pump inhibitors: a systematic review and meta-analysis. J Gastroenterol 2013; 48: 830–38. CrossRef MEDLINE 20. Rostom A, Muir K, Dube C, et al.: Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors. Drug Healthc Patient Saf 2009; 1: 47–71. CrossRef MEDLINE PubMed Central 21. Scally B, Emberson JR, Spata E, et al.: Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. Lancet Gastroenterol Hepatol 2018; 3: 231–41. CrossRef MEDLINE 22. Wang X, Tian HJ, Yang HK, et al.: Meta-analysis: Cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis. Eur J Gastroenterol Hepatol 2011; 23: 876–80. CrossRef MEDLINE 23. Rane PP, Guha S, Chatterjee S, et al.: Prevalence and predictors of non-evidence based proton pump inhibitor use among elderly nursing home residents in the US. Res Social Adm Pharm 2017; 13: 358–63. CrossRef MEDLINE 24. Hoffmann F, Glaeske G, Schmiemann G: Steigende Verordnungszahlen von Protonenpumpenhemmern im ambulant-ärztlichen Bereich über die Jahre 2005-2013. Z Gastroenterol 2015; 53: 95–100. CrossRef MEDLINE 25. Haastrup PF, Thompson W, Søndergaard J, et al.: Side Effects of Long-Term Proton Pump Inhibitor Use: A Review. Basic Clin Pharmacol Toxicol 2018; 123: 114–21. CrossRef MEDLINE 26. Targownik LE, Fisher DA, Saini SD. AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review. Gastroenterology 2022; 162: 1334–42. CrossRef MEDLINE 27. Beschluss der Bundesärztekammer über die Querschnitts-Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten, Gesamtnovelle 2020. Dtsch Arztebl 2020; 117 (40): A-1883/B-1603. VOLLTEXT 28. Carson JL, Sieber F, Cook DR, et al.: Liberal versus restrictive blood transfusion strategy: 3-year survival and cause of death results from the FOCUS randomised controlled trial. Lancet 2015; 385 (9974): 1183–89. CrossRef MEDLINE 29. Carson JL, Stanworth SJ, Denis JA, et al.: Transfusion thresholds for guiding red blood cell transfusion. Cochrane Database Syst Rev 2021; 12 (12): CD002042 CrossRef MEDLINE PubMed Central 30. Berger MD, Gerber B, Arn K, et al.: Significant reduction of red blood cell transfusion requirements by changing from a double-unit to a single-unit transfusion policy in patients receiving intensive chemotherapy or stem cell transplantation. Haematologica 2012; 97: 116–22. CrossRef MEDLINE PubMed Central 31. Leahy MF, Trentino KM, May C, et al.: Blood use in patients receiving intensive chemotherapy for acute leukemia or hematopoietic stem cell transplantation: the impact of a health system-wide patient blood management program. Transfusion 2017; 57: 2189–96. CrossRef MEDLINE 32. Amano K, Baracos VE, Hopkinson JB: Integration of palliative, supportive, and nutritional care to alleviate eating-related distress among advanced cancer patients with cachexia and their family members. Crit Rev in Oncol Hematol 2019; 143: 117–23. CrossRef MEDLINE 33. Tobberup R, Thoresen L, Falkmer UG, et al.: Effects of current parenteral nutrition treatment on health-related quality of life, physical function nutritional status, survival and adverse events exclusively in patients with advanced cancer: A systematic literature review. Crit Rev Oncol Hematol 2019; 139: 96–107. CrossRef MEDLINE 34. Arends J, Strasser F, Gonella S, et al.: Cancer cachexia in adult patients: ESMO Clinical Practice. ESMO Open 2021; 6 (3): 100092. CrossRef MEDLINE PubMed Central 35. Orrevall Y: Nutritional support at the end of life. Nutrition 2015; 31: 615–6. CrossRef MEDLINE 36. Arends J, Bachmann P, Bracos V, et al.: ESPEN guidelines on nutrition in cancer patients. Clin Nutr 2017; 36: 11–48 CrossRef MEDLINE 37. Arends J, Jordan K: Supplemental parenteral nutrition: decisions based on weak evidence. ESMO Open 2020; 5 (4): e000831. CrossRef MEDLINE PubMed Central 38. Raijmakers NJH, van Zuylen L, Costantini M, et al.: Artificial nutrition and hydration in the last week of life in cancer patients. A systematic literature review of practices and effects. Ann Oncol 2022; 22: 1478–86. CrossRef MEDLINE 39. Bouleuc C, Anota A, Cornet C, et al.: Impact on Health-related Quality of Life of Parenteral Nutrition for Patients with Advanced Cancer Cachexia: results from a Randomized Controlled Trial. Oncologist 2020; 25: e843–51. CrossRef MEDLINE PubMed Central 40. McCann RM, Hall WJ, Groth-Juncker A: Comfort care for terminally ill patients. The appropriate use of nutrition and hydration. JAMA 1994; 272: 1263–6. CrossRef MEDLINE 41. Chow R, Bruera E, Arends J, et al.: Enteral and parenteral nutrition in cancer patients a comparison of complication rates: an updated systematic review and (cumulative) meta-analysis. Support Care Cancer 2020; 28: 979–1010. CrossRef MEDLINE 42. Collet J-P, Thiele H, Barbato E, et al.: 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021; 42: 1289–367 CrossRef MEDLINE 43. Thiele H, Bauersachs J, Mehilli J, et al.: Kommentar zu den 2020er-Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) zum Management des akuten Koronarsyndroms bei Patienten ohne persistierende ST-Strecken-Hebung. Kardiologe 2021; 15: 19–31. CrossRef 44. Hindricks G, Potpara T, Dagres N, et al.: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC); Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42: 373–498 CrossRef MEDLINE 45. Rourke EJ: Ten Years of Choosing Wisely to Reduce Low-Value Care. New Engl J Med 2022; 386 (14): 1293–5. CrossRef MEDLINE